# EDGAR Filing Document

**Accession Number:** 0001776985
**File Stem:** 0001776985-26-000016
**Filing Date:** 2026-3
**Character Count:** 98944
**Document Hash:** f7a684790340d550e6f4c18651dbd426
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001776985-26-000016.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001776985-26-000016

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 37

**CONFORMED PERIOD OF REPORT**: 20260310

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioNTech SE
- **CENTRAL INDEX KEY:** 0001776985
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39081
- **FILM NUMBER:** 26737114

**BUSINESS ADDRESS:**
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55131
- **BUSINESS PHONE:** 0049613190840

**MAIL ADDRESS:**
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55131

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

<br>**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**FOR THE MONTH OF MARCH 2026**

**COMMISSION FILE NUMBER 001-39081** 

**BioNTech SE**<br> (Translation of registrant's name into English)

**An der Goldgrube 12**

**D-55131 Mainz**

**Germany**

**+49 6131-9084-0**<br> (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K**

On March 10, 2026, BioNTech SE (the "Company") issued a press release announcing its full year 2025 financial results and corporate update and details of a conference call to be held at 8:00 am EDT on March 10, 2026 to discuss the results. The press release and the conference call presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein.

The information contained in Exhibits 99.1 and 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

------

**SIGNATURE**

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| **BioNTech SE** | **BioNTech SE** | | |
| By: | /s/ Ramon Zapata-Gomez | By: | /s/ Dr. Sierk Poetting |
|  | Name: Ramon Zapata-Gomez |  | Name: Dr. Sierk Poetting |
|  | Title: Chief Financial Officer |  | Title: Chief Operating Officer |

---

Date: March 10, 2026

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| <u>Exhibit</u> | <u>Description of Exhibit</u> |
| 99.1 | <u>[BioNTech Announces](a991bntxq4_pr.htm)[Fourth Quarter and](a991bntxq4_pr.htm)[Full Year 2025 Financial Results and Corpora](a991bntxq4_pr.htm)[te Update](a991bntxq4_pr.htm)</u> |
| 99.2 | <u>[Fourth Quarter and Full Year 2025: Financial Results and Corporate Update](ex992bntx4qfy2025present.htm)</u> |

---

## Exhibit 99.1

**Exhibit 99.1**

![image_0a.jpg](image_0a.jpg)

**BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***BioNTech on track for a catalyst-rich year*** *with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***Increased focus on PD-L1***<sup>1</sup>***/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials*** *planned to be ongoing for year-end in collaboration with Bristol Myers Squibb*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***Full year 2025 revenues of €2.9 billion***<sup>2</sup>*, net loss of €1.1 billion (adjusted*<sup>3</sup> *net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.31*<sup>4</sup>*) (adjusted*<sup>3</sup> *diluted loss per share of €0.48 ($0.55*<sup>4</sup>*))*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***Strong financial position continues to de-risk execution*** *with cash, cash equivalents and security investments of €17.2 billion*<sup>5</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***Expect 2026 total revenues of €2.0 billion to €2.3 billion,*** *adjusted*<sup>3</sup> *R&D expenses between €2.2-2.5 billion and adjusted*<sup>3</sup> *SG&A expenses*<sup>7</sup> *between €700-800 million*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***BioNTech co-founders Ugur Sahin and Özlem Türeci to establish an independent company*** *with a focus on next-generation mRNA innovations; management transition by end of 2026*

**Conference call and webcast scheduled for March 10, 2026, at 8:00 a.m. EDT (1:00 p.m. CET)**

**MAINZ, Germany, March 10, 2026 (GLOBE NEWSWIRE)** -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today reported financial results for the three months and full year ended December 31, 2025 and provided an update on its corporate progress.

"2025 was a year of strong execution and pipeline momentum, marked by substantial progress in delivering on our strategy. We advanced our oncology pipeline by moving multiple programs into late-stage development and initiated trials assessing novel-novel combination approaches with the aim of delivering differentiated therapeutic profiles," said **Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech**. "With our unique pipeline and strong financial position, we remain committed to leveraging our pioneering position in the immuno-oncology space with next-generation agents designed to elevate outcomes for patients with cancer. 2026 is poised to be a pivotal year with multiple readouts expected across our portfolio, representing a significant step toward our objective of becoming a multi-product company by 2030."

**Financial Review for Fourth Quarter and Full Year 2025**<sup>3</sup>

---

| | | | | |
|:---|:---|:---|:---|:---|
| *in millions €,* <br>*except per share data* | **Full Year 2025** | **Full Year 2025** | **Full Year 2024** | **Full Year 2024** |
| *in millions €,* <br>*except per share data* | **IFRS Results** | **Adjusted Results**<sup>3</sup> | **IFRS Results** | **Adjusted Results**<sup>3</sup> |
| **Revenues** | 2869.9 | 2869.9 | 2751.1 | 2751.1 |
| **Net profit / (loss)** | (1136.1) | (117.1) | (665.3) | 121.7 |
| **Diluted earnings / (loss) per share** | (4.70) | (0.48) | (2.77) | 0.50 |

---

------

![image_0a.jpg](image_0a.jpg)

---

| | | | | |
|:---|:---|:---|:---|:---|
| *in millions €,* <br>*except per share data* | **Fourth Quarter 2025** | **Fourth Quarter 2025** | **Fourth Quarter 2024** | **Fourth Quarter 2024** |
| *in millions €,* <br>*except per share data* | **IFRS Results** | **Adjusted Results**<sup>3</sup> | **IFRS Results** | **Adjusted Results**<sup>3</sup> |
| **Revenues** | 907.4 | 907.4 | 1190.0 | 1190.0 |
| **Net profit / (loss)** | (305.0) | (79.5) | 259.5 | 432.4 |
| **Diluted earnings / (loss) per share** | (1.25) | (0.33) | 1.08 | 1.79 |

---

**Revenues** for the three months ended December 31, 2025, were €907.4 million, compared to €1,190.0 million for the comparative prior year period. For the year ended December 31, 2025, revenues were €2,869.9 million, compared to €2,751.1 million for the comparative prior year period. The quarterly year-on-year decrease was primarily driven by lower sales of the Company's COVID-19 vaccines due to reduced market demand. The full year revenue increase was primarily driven by revenues related to BioNTech's collaboration with Bristol Myers Squibb Company ("BMS") that were recognized in the third quarter of 2025.

**Research and development** ("R&D") expenses were €505.4 million for the three months ended December 31, 2025, compared to €611.8 million for the comparative prior year period. For the year ended December 31, 2025, R&D expenses were €2,104.9 million, compared to €2,254.2 million for the comparative prior year period. Both quarterly and full year year-on-year decreases were mainly driven by cost savings resulting from active portfolio management and positive effects resulting from our pumitamig cost sharing with BMS, partly offset by the acceleration of late-stage trials for immuno-oncology ("IO") and antibody-drug conjugate ("ADC") development programs.

**Adjusted R&D expenses** were €505.4 million for the three months ended December 31, 2025, compared to €530.3 million for the comparative prior year period. For the year ended December 31, 2025, adjusted R&D expenses were €2,019.5 million, compared to €2,172.7 million for the comparative prior year period. For 2025 and 2024, the Company's adjusted R&D expenses exclude impairments.

**Sales, general and administrative** ("SG&A") expenses<sup>7</sup> were €217.9 million for the three months ended December 31, 2025, compared to €132.1 million for the comparative prior year period. For the year ended December 31, 2025, SG&A expenses were €624.4 million, compared to €599.0 million for the comparative prior year period. Both quarterly and full year year-on-year increases were mainly driven by our ongoing commercial build-up, partly offset by lower costs for external services.

**Other operating result** was negative €173.6 million during the three months ended December 31, 2025, compared to negative €54.0 million for the comparative prior year period. For the year ended December 31, 2025, other operating result was negative €903.7 million compared to negative €670.9 million for the prior year period. Both quarterly and full year year-on-year decreases were primarily driven by expenses from settlements of contractual disputes, expenses in connection with our pipeline prioritization and foreign exchange differences.

**Adjusted other operating result** was €21.4 million during the three months ended December 31, 2025, compared to negative €1.6 million for the comparative prior year period. For the year ended December 31, 2025, other operating result was negative €0.6 million compared to negative €13.5 million for the prior year period. For fiscal years 2025 and 2024, our quarterly and full year adjusted other operating results exclude expenses in connection with the settlements of legal proceedings. In addition, our quarterly and full year adjusted other operating results during fiscal year 2025 exclude employee-related costs in connection with our pipeline prioritization and a bargain purchase.

**Net loss** was €305.0 million for the three months ended December 31, 2025, compared to a net income of €259.5 million for the comparative prior year period. For the year ended December 31,

------

![image_0a.jpg](image_0a.jpg)

2025, net loss was €1,136.1 million, compared to a net loss of €665.3 million for the comparative prior year period.

**Adjusted net loss** was €79.5 million for the three months ended December 31, 2025, compared to an adjusted net profit of €432.4 million for the comparative prior year period. For the year ended December 31, 2025, adjusted net loss was €117.1 million, compared to an adjusted net profit of €121.7 million for the comparative prior year period.

**Diluted loss per share** was €1.25 for the three months ended December 31, 2025, compared to diluted earnings per share of €1.08 for the comparative prior year period. For the year ended December 31, 2025, diluted loss per share was €4.70, compared to diluted loss per share of €2.77 for the comparative prior year period.

**Adjusted diluted loss per share** was €0.33 for the three months ended December 31, 2025, compared to adjusted diluted earnings per share of €1.79 for the comparative prior year period. For the year ended December 31, 2025, adjusted diluted loss per share was €0.48, compared to adjusted diluted earnings per share of €0.50 for the comparative prior year period.

**Cash, cash equivalents and security investments** as of December 31, 2025, were €17,235.6 million, comprising €7,675.4 million in cash and cash equivalents, €7,158.5 million in current security investments disclosed as financial assets and €2,401.7 million in non-current security investments disclosed as financial assets.

**Shares outstanding** as of December 31, 2025, were 251,325,340, excluding 7,702,147 shares held in treasury.

"Our strong financial position fuels and de-risks our R&D activities as we prepare for multiple product launches in the coming years. Our financial discipline, active portfolio management and targeted investments will continue to drive innovation and create long-term value for BioNTech's stakeholders," **said Ramón Zapata, Chief Financial Officer at BioNTech**.

**2026 Financial Year Guidance**<sup>6</sup>**:**

---

| | |
|:---|:---|
| **Revenues for the 2026 financial year** | **€2,000 – €2,300 m** |

---

In 2026, BioNTech anticipates lower COVID-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets. The United States continues to be a competitive and dynamic market, where as a result, lower revenues are expected. In Europe, we expect lower revenues as we defend our market share and begin managing the transition of multi-year contracts. In Germany, specifically, BioNTech recognizes direct sales of its COVID-19 vaccines as revenue. Hence, the anticipated declines in the Company's sales of COVID-19 vaccines in the country will have a direct impact on its topline, whereas revenues outside of Germany only affect the Company's topline as part of the 50% gross profit split with our partner Pfizer Inc. ("Pfizer"). Per the outlined partnership terms, revenues from the collaboration with BMS in 2026 are expected to be broadly in line with 2025. Revenues from the pandemic preparedness contract with the German government and service businesses are expected to remain stable.

**Planned 2026 Financial Year Adjusted Expenses**<sup>6</sup>**:**

---

| | |
|:---|:---|
| **Adjusted R&D expenses** | **€2,200 – €2,500 m** |
| **Adjusted SG&A expenses** | **€700 – €800 m** |

---

------

![image_0a.jpg](image_0a.jpg)

BioNTech will continue to focus investments on R&D and scaling the business for late-stage development and commercial readiness in oncology, while remaining cost-disciplined. Strategic capital allocation will continue to foster innovation and be a key driver of the Company's trajectory. As part of BioNTech's strategy, the Company may continue to evaluate appropriate corporate development opportunities with the aim of driving sustainable long-term growth and creating future value.

The full audited consolidated financial statements as of and for the year ended December 31, 2025, can be found in BioNTech's Annual Report on Form 20-F filed today with the U.S. Securities and Exchange Commission ("SEC") and available at <u>www.sec.gov</u>.

**Endnotes**

<sup>1</sup> An overview of abbreviations is compiled in a directory at the end of this press release.

<sup>2</sup> All numbers in this press release have been rounded.

<sup>3</sup> In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found at the end of this press release and in BioNTech's Report on Form 20-F for the year ended December 31, 2025 filed on March 10, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards.

<sup>4</sup> Calculated applying the average foreign exchange rate for the year ended December 31, 2025, as published by the German Central Bank (Deutsche Bundesbank).

<sup>5</sup> As of December 31, 2025.

<sup>6</sup> Excludes risks that are not yet known and/or quantifiable and related activities. It includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions ("M&A") transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech's Report on Form 20-F for the year ended December 31, 2025 filed on March 10, 2026, which is available at <u>www.sec.gov</u>.

<sup>7</sup> Sales, general and administrative expenses ("SG&A") include sales and marketing expenses as well as general and administrative expenses. Adjusted SG&A expenses include adjusted sales and marketing expenses as well as adjusted general and administrative expenses.

**Operational Review for the Fourth Quarter and Full Year 2025, Key Post Period-End Events and Outlook on 2026**

***Corporate Update for the Fourth Quarter 2025 and Post Period Events***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On March 10, 2026, BioNTech announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Özlem Türeci, M.D. The new company with distinct resources, operations and funding options will advance next-generation mRNA innovations. BioNTech plans to contribute related rights and mRNA technologies to the new company to enable and support the prioritized development of next-generation mRNA innovations with disruptive potential. With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike. Ugur Sahin and Özlem Türeci will transition into the management of their new company by the end of 2026 after their current service agreements end. BioNTech's Supervisory Board has initiated an executive search to identify successors for the positions to ensure a smooth transition and seamless execution of BioNTech's strategy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On March 1, Kylie Jimenez joined BioNTech's Management Board as Chief People Officer ("CPO"). The appointment is in line with BioNTech's strategy to become a multi-product

------

![image_0a.jpg](image_0a.jpg)

biopharmaceutical company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. Kylie will focus on attracting, developing and retaining talent, while strengthening an inclusive culture.

***Select Oncology Pipeline Updates***

*Next-Generation Immunomodulators and Combinations*

**Pumitamig (BNT327/BMS986545)** is a bispecific immunomodulator candidate combining PD-L1 checkpoint inhibition with VEGF-A neutralization that is being developed in collaboration with BMS.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A global Phase 3 clinical trial in patients with first-line triple-negative breast cancer ("TNBC") (ROSETTA Breast-01; <u>NCT07173751</u>) is enrolling.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A global Phase 2/3 clinical trial to evaluate pumitamig in first-line microsatellite stable colorectal cancer ("CRC") (ROSETTA CRC-203; <u>NCT07221357</u>) is enrolling.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A global Phase 2/3 clinical trial to evaluate pumitamig in first-line gastric cancer (ROSETTA Gastric-204; <u>NCT07221149</u>) is enrolling.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A global Phase 2/3 clinical trial (ROSETTA Lung-02; <u>NCT06712316</u>) is ongoing to evaluate pumitamig in combination with chemotherapy compared to pembrolizumab and chemotherapy in patients with first-line non-small cell lung cancer ("NSCLC"). The Phase 2 part of the seamless Phase 2/3 trial achieved full enrollment and the Phase 3 portion is currently recruiting. Data from the Phase 2 part of the trial are expected in 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Additional pivotal Phase 2/3 and Phase 3 trials are planned to start in 2026, in unresectable stage III NSCLC (ROSETTA Lung-201, <u>NCT07361497</u>), first-line PD-L1 ≥ 50% NSCLC (ROSETTA Lung-202, <u>NCT07361510</u>) and first-line head and neck squamous cell carcinoma ("HNSCC") (ROSETTA HNSCC-205).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Pumitamig is also being evaluated in additional solid tumor indications, including first-line hepatocellular carcinoma ("HCC"), second-line glioblastoma ("GBM"), first-line pancreatic ductal adenocarcinoma ("PDAC") and first-line renal cell carcinoma ("RCC") in various Phase 1/2 and Phase 2 trials, both as monotherapy and in combination with standard of care.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In 2025, BioNTech initiated several signal-seeking clinical trials to evaluate pumitamig with the Company's proprietary assets. These trials will inform the dose selection for pumitamig and explore anti-tumor activity in multiple tumors for later-stage development.

**Gotistobart (BNT316/ONC-392)** is a tumor microenvironment-selective regulatory T cell depletion candidate that targets CTLA-4 and is being developed in collaboration with OncoC4, Inc. ("OncoC4").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A global Phase 3 clinical trial (PRESERVE-003; <u>NCT05671510</u>) is ongoing to evaluate the efficacy and safety of gotistobart as monotherapy in patients with metastatic squamous NSCLC ("sqNSCLC") that progressed under previous platinum-based chemotherapy and PD-(L)1-inhibitor treatment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In December 2025, data from the non-pivotal dose-confirmation stage, the first of two stages of the global Phase 3 clinical trial, were presented at the International Association for the Study of Lung Cancer ("IASLC") American Society of Clinical Oncology ("ASCO") 2025 North America Conference on Lung Cancer ("NACLC"). Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard of care chemotherapy and a manageable safety profile in patients with squamous NSCLC whose disease had progressed following anti-PD-(L)1 therapy and platinum-based chemotherapy.

------

![image_0a.jpg](image_0a.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Based on current event accrual projections, interim data from the pivotal stage of the two-stage Phase 3 clinical trial are expected in 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In January 2026, gotistobart received Orphan Drug Designation from the U.S. Food and Drug Administration ("FDA") for the treatment of squamous NSCLC. In 2022, gotistobart received Fast Track Designation from the FDA for the treatment of patients with metastatic NSCLC whose disease progressed on prior anti-PD-(L)1 therapy.

*Antibody-Drug Conjugates*

**Trastuzumab pamirtecan** (BNT323/DB-1303) is an ADC candidate targeting HER2 that is being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. ("DualityBio").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A Phase 1/2 clinical trial (<u>NCT05150691</u>) is ongoing to evaluate trastuzumab pamirtecan in patients with advanced HER2-expressing tumors. A potentially registrational cohort with HER2-expressing (IHC3+, 2+, 1+ or ISH-positive) patients with recurrent endometrial cancer is ongoing. Data are expected to be shared at a medical conference in 2026. BioNTech and DualityBio plan to file a biologics license application ("BLA") in 2026, subject to regulatory feedback from the FDA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A global Phase 3 clinical trial (DYNASTY-Breast02, <u>NCT06018337</u>) to evaluate trastuzumab pamirtecan in patients with HR-positive, HER2-low metastatic breast cancer is ongoing. Based on current event accrual projections, data are expected in 2026.

**BNT324/DB-1311** is an ADC candidate targeting B7H3 that is being developed in collaboration with DualityBio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In February 2026, updated data from a Phase 1/2 clinical trial (<u>NCT05914116</u>) were presented at the ASCO Genitourinary Cancers Symposium. BNT324/DB-1311 demonstrated durable efficacy in heavily pretreated metastatic castration-resistant prostate cancer ("mCRPC") patients with no new safety signals reported.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A Phase 3 clinical trial (<u>NCT07365995</u>) to evaluate BNT324/DB-1311 compared to docetaxel in patients with mCRPC is expected to initiate in 2026.

*mRNA Cancer Immunotherapies*

**BNT113** is an mRNA cancer immunotherapy candidate and based on BioNTech's fully owned, off-the-shelf FixVac platform, encoding the two oncoproteins E6 and E7 that are frequently found in human papillomavirus type 16 positive ("HPV16+") solid tumors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In December 2025, the FDA granted Fast Track designation to BNT113 for the treatment of patients with PD-L1+, HPV16+ HNSCC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Based on current event accrual projections, data are expected in 2026 from the first interim analysis of the Phase 3 part of the ongoing Phase 2/3 clinical trial (AHEAD-MERIT; <u>NCT04534205</u>) evaluating BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent or metastatic, PD-L1+, HPV16+ HNSCC.

**Autogene cevumeran** (BNT122/RO7198457) is an mRNA cancer immunotherapy candidate for individualized neoantigen-specific immunotherapy ("iNeST") that is being developed in collaboration with Genentech, Inc. ("Genentech"), a member of the Roche Group ("Roche").

------

![image_0a.jpg](image_0a.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• An update from the ongoing Phase 2 clinical trial in Stage II (high-risk)/Stage III circulating tumor DNA positive ("ctDNA+") adjuvant colorectal cancer ("CRC") is expected in early 2026. Data read-out from the final analysis of this trial has been updated from 2026 to 2027, given that events have accrued more slowly than projected.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• BioNTech and Roche, the sponsor of the trial, have decided to discontinue the Phase 2 clinical trial (IMcode004; <u>NCT06534983</u>) evaluating autogene cevumeran as an adjuvant treatment in combination with nivolumab compared to nivolumab alone in patients with high-risk muscle-invasive urothelial carcinoma due to the rapidly emerging treatment landscape and shifting standard of care. The companies will focus on advancing autogene cevumeran in the currently ongoing randomized Phase 2 clinical trials in adjuvant pancreatic ductal adenocarcinoma ("PDAC") and adjuvant CRC.

**Expected 2026 Milestones**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Program** | **Modality** | **Trial Readout Phase** | **Indication** |
| **Late-Stage Trial Readouts** | **Trastuzumab pamirtecan**<sup>3</sup> | ADC | Single-arm Phase 2 | 2L+ HER2-expressing endometrial cancer |
| **Late-Stage Trial Readouts** | **Trastuzumab pamirtecan**<sup>3</sup> | ADC | Phase 3 interim analysis | Chemo naïve HR+ HER2-low breast cancer |
| **Late-Stage Trial Readouts** | **Gotistobart**<sup>2</sup> | Immunomodulator | Phase 3 interim analysis | 2L+ sqNSCLC |
| **Late-Stage Trial Readouts** | **Gotistobart**<sup>2</sup> | Immunomodulator | Phase 2 | 2L+ mCRPC |
| **Late-Stage Trial Readouts** | **BNT113** | mRNA cancer immunotherapy | Phase 3 interim analysis | 1L HPV16+ PD-L1+ HNSCC |
| **Late-Stage Trial Readouts** | **Pumitamig**<sup>1</sup> | Immunomodulator | Phase 3 in China interim analysis | 1L TNBC |

---

------

![image_0a.jpg](image_0a.jpg)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Early-Stage Pumitamig & ADC Trial Readouts** | **Pumitamig**<sup>1</sup> | Immunomodulator | Phase 2 | 1L NSCLC |
| **Early-Stage Pumitamig & ADC Trial Readouts** | **Pumitamig**<sup>1</sup> | Immunomodulator | Phase 2 | 1L extensive-stage small-cell lung cancer ("ES-SCLC") |
| **Early-Stage Pumitamig & ADC Trial Readouts** | **Pumitamig**<sup>1</sup> | Immunomodulator | Phase 2 in China | 1L HCC |
| **Early-Stage Pumitamig & ADC Trial Readouts** | **Pumitamig**<sup>1</sup> | Immunomodulator | Phase 2 in China | 1L microsatellite stable colorectal cancer ("MSS-CRC") |
| **Early-Stage Pumitamig & ADC Trial Readouts** | **Pumitamig**<sup>1</sup> **+**<br>**Trastuzumab pamirtecan (HER2-ADC)**<sup>3</sup> | Immunomodulator<br>+ ADC | Phase 1/2 | Breast cancer |
| **Early-Stage Pumitamig & ADC Trial Readouts** | **Pumitamig**<sup>1</sup> **+ BNT324/DB-1311 (B7H3-ADC)**<sup>3</sup> | Immunomodulator<br>+ ADC | Phase 1/2 | Advanced solid tumors |
| **Early-Stage Pumitamig & ADC Trial Readouts** | **Pumitamig**<sup>1</sup> **+ BNT324/DB-1311 (B7H3-ADC)**<sup>3</sup> | Immunomodulator<br>+ ADC | Phase 2 | NSCLC/SCLC |
| **Early-Stage Pumitamig & ADC Trial Readouts** | **Pumitamig**<sup>1</sup> **+ BNT325/DB-1305 (TROP2-ADC)**<sup>3</sup> | Immunomodulator<br>+ ADC | Phase 2 | TNBC |
| **Early-Stage Pumitamig & ADC Trial Readouts** | **Pumitamig**<sup>1</sup> **+ BNT326/YL202 (HER3-ADC)**<sup>4</sup> | Immunomodulator<br>+ ADC | Phase 1/2 | NSCLC |
| **Early-Stage Pumitamig & ADC Trial Readouts** | **BNT324/DB-1311 (B7H3-ADC)**<sup>3</sup> | ADC | Phase 1/2 | 2L+ mCRPC |
| **Phase 3 Trial Initiations** | **Pumitamig**<sup>1</sup> | Immunomodulator | Phase 3 | 1L MSS-CRC |
| **Phase 3 Trial Initiations** | **Pumitamig**<sup>1</sup> | Immunomodulator | Phase 3 | 1L HER2- PD-L1+ gastric cancer |
| **Phase 3 Trial Initiations** | **Pumitamig**<sup>1</sup> | Immunomodulator | Phase 3 | 1L HNSCC |
| **Phase 3 Trial Initiations** | **Pumitamig**<sup>1</sup> | Immunomodulator | Phase 3 | NSCLC stage 3 unresectable |
| **Phase 3 Trial Initiations** | **Pumitamig**<sup>1</sup> | Immunomodulator | Phase 3 | 1L NSCLC PD-L1 high |
| **Phase 3 Trial Initiations** | **BNT324 /DB-1311 (B7H3-ADC)**<sup>3</sup> | ADC | Phase 3 | 1L mCRPC |
| **BLA Submission** | **Trastuzumab pamirtecan (HER2-ADC)**<sup>3</sup> | ADC | - | 2L+ HER2-expressing endometrial cancer |

---

Partnered with: 1. BMS; 2. OncoC4; 3. DualityBio; 4. MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink").

**Upcoming Investor and Analyst Events**

• BioNTech First Quarter 2026 Financial Results and Corporate Update: May 5, 2026

• BioNTech Annual General Meeting: May 15, 2026

------

![image_0a.jpg](image_0a.jpg)

**Conference Call and Webcast Information**

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, March 10, 2026, at 8:00 a.m. EDT (1:00 p.m. CET) to report its financial results and provide a corporate update for the fourth quarter and full year 2025.

To access the live conference call via telephone, please register <u>via this link</u>. Once registered, dial-in numbers and a PIN number will be provided.

The slide presentation and audio of the webcast will be available <u>via this link</u>.

Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page of the Investor section of the Company's website at <u>www.BioNTech.com</u>. A replay of the webcast will be made available shortly after the closing of the call and archived on the Company's website for 30 days following the call.

**About BioNTech**

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, Pfizer and Regeneron.

For more information, please visit <u>www.BioNTech.com</u>.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech's leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; the terms of the preliminary discussions between BioNTech and the co-founders regarding the potential contribution of certain BioNTech assets to an independent company; BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or clinical trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech's expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational clinical trials, and the registrational potential of any clinical trial BioNTech may initiate; discussions with regulatory agencies; BioNTech's expectations with respect to intellectual property; the impact of BioNTech's collaboration and licensing agreements, including BioNTech's partnership with Bristol Myers Squibb; BioNTech's expectations with respect to developments in law, public policy, and

------

![image_0a.jpg](image_0a.jpg)

international trade; BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech's expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech's current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or annual booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech's other product candidates; the timing of and BioNTech's ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and market its product candidates, if approved; BioNTech's ability to manage its development and related expenses; regulatory and political developments; BioNTech's ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Annual Report on Form 20-F for the period ended December 31, 2025 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

------

![image_0a.jpg](image_0a.jpg)

**CONTACTS**

**Investor Relations**

Douglas Maffei, PhD

<u>Investors@biontech.de</u> 

**Media Relations**

Jasmina Alatovic

<u>Media@biontech.de</u>

**Abbreviation Overview**

---

| | |
|:---|:---|
| 1L | First line |
| 2L | Second line |
| adj. | Adjuvant |
| B7H3 | B7 homologue B3 |
| (MSS-)CRC | (Microsatellite stable-) colorectal cancer |
| ctDNA | Circulating tumor DNA |
| CTLA-4 | Cytotoxic T-lymphocyte-associated protein |
| ES-SCLC | Extensive-stage small cell lung cancer |
| GBM | Glioblastoma |
| HCC | Hepatocellular carcinoma |
| HER2 (or HER3) | Human epidermal growth factor receptor 2 (or 3) |
| HNSCC | Head and neck squamous cell carcinoma |
| HPV16 | Human papilloma virus 16 |
| HR | Hormone receptor |
| IHC3+, 2+, 1+ | Immunohistochemistry score 1+ (or 2+ or 3+) |
| ISH-positive | *In-situ* hybridization positive |
| mCRPC | Metastatic castration resistant prostate cancer |
| RCC | Renal cell carcinoma |
| (sq) NSCLC | (Squamous) non-small cell lung cancer |
| PDAC | Pancreatic ductal adenocarcinoma |
| PD-(L)1 | Programmed cell death protein (death-ligand) 1 |
| TNBC | Triple-negative breast cancer |
| TROP2 | Trophoblast cell-surface antigen 2 |
| VEGF-A | Vascular endothelial growth factor A |

---

------

![image_0a.jpg](image_0a.jpg)

 **Consolidated Statements of Profit or Loss (IFRS Results)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** <br>**December 31,**  | **Three months ended** <br>**December 31,**  | **Years ended** <br>**December 31,**  | **Years ended** <br>**December 31,**  |
| | **2025** | **2024** | **2025** | **2024** |
| <br><br>*(in millions €, except per share data)* | *(unaudited)* | *(unaudited)* |  |  |
| Revenues | 907.4 | 1190.0 | 2869.9 | 2751.1 |
| Cost of sales | (333.3) | (243.5) | (641.8) | (541.3) |
| Research and development expenses | (505.4) | (611.8) | (2104.9) | (2254.2) |
| Sales and marketing expenses | (49.3) | (21.3) | (110.0) | (67.9) |
| General and administrative expenses  | (168.6) | (110.8) | (514.4) | (531.1) |
| Other operating expenses  | (208.0) | (91.6) | (1088.3) | (811.5) |
| Other operating income  | 34.4 | 37.6 | 184.6 | 140.6 |
| **Operating profit / (loss)** | **(322.8)** | **148.6** | **(1404.9)** | **(1314.3)** |
| Finance income | 99.6 | 165.2 | 423.9 | 664.0 |
| Finance expenses | (4.2) | (12.6) | (69.8) | (27.4) |
| **Profit / (Loss) before tax** | **(227.4)** | **301.2** | **(1050.8)** | **(677.7)** |
| Income taxes | (77.6) | (41.7) | (85.3) | 12.4 |
| **Net profit / (loss)** | **(305.0)** | **259.5** | **(1136.1)** | **(665.3)** |
| **Earnings / (Loss) per share** |  |  |  |  |
| Basic earnings / (loss) per share | (1.25) | 1.08 | (4.70) | (2.77) |
| Diluted earnings / (loss) per share | (1.25) | 1.08 | (4.70) | (2.77) |

---

------

![image_0a.jpg](image_0a.jpg)

**Condensed Consolidated Statements of Profit or Loss (Adjusted Results)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Adjusted Results (non-IFRS measures)**<sup>1</sup> | **Three months ended** <br>**December 31,**  | **Three months ended** <br>**December 31,**  | **Years ended** <br>**December 31,**  | **Years ended** <br>**December 31,**  |
|  | **2025** | **2024** | **2025** | **2024** |
| *(in millions €, except per share data)* | *(unaudited)* | *(unaudited)* |  |  |
| Adjusted cost of sales | (302.8) | (204.5) | (611.3) | (493.2) |
| Adjusted research and development expenses | (505.4) | (530.3) | (2019.5) | (2172.7) |
| Adjusted other operating expenses  | (13.0) | (39.2) | (170.2) | (154.1) |
| Adjusted other operating income  | 34.4 | 37.6 | 169.6 | 140.6 |
| **Adjusted operating profit / (loss)** | **(97.3)** | **321.5** | **(385.9)** | **(527.3)** |
| **Adjusted profit / (loss) before tax** | **(1.9)** | **474.1** | **(31.8)** | **109.3** |
| **Adjusted net profit / (loss)**<sup>2</sup> | **(79.5)** | **432.4** | **(117.1)** | **121.7** |
| **Adjusted earnings / (loss) per share** |  |  |  |  |
| Adjusted basic earnings / (loss) per share | (0.33) | 1.80 | (0.48) | 0.51 |
| Adjusted diluted earnings / (loss) per share | (0.33) | 1.79 | (0.48) | 0.50 |

---

<sup>1</sup> Certain adjusted results presented in this table are identical to our results under IFRS Accounting Standards. Reconciliation of all other adjusted results to our IFRS results can be found at the end of this press release and in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov.

<sup>2</sup> Tax effects are not considered as part of our non-IFRS adjustments

------

![image_0a.jpg](image_0a.jpg)

**Consolidated Statements of Financial Position**

---

| | | |
|:---|:---|:---|
|  | **December 31,**  | **December 31,**  |
| *(in millions €)* | **2025** | **2024** |
| **Assets**  |  |  |
| **Non-current assets**  |  |  |
| Goodwill | 367.9 | 380.6 |
| Other intangible assets  | 1606.0 | 790.4 |
| Property, plant and equipment  | 1080.9 | 935.3 |
| Right-of-use assets | 210.2 | 248.1 |
| Contract assets  | 2.0 | 9.8 |
| Other financial assets | 2554.2 | 1254.0 |
| Other non-financial assets | 7.3 | 26.3 |
| Deferred tax assets  | 13.5 | 81.7 |
| **Total non-current assets**  | **5842.0** | **3726.2** |
| **Current assets** |  |  |
| Inventories  | 110.7 | 283.3 |
| Trade and other receivables  | 924.2 | 1463.9 |
| Contract assets  | 8.1 | 10.0 |
| Other financial assets  | 7201.8 | 7021.7 |
| Other non-financial assets | 173.8 | 212.7 |
| Income tax assets  | 52.6 | 50.0 |
| Cash and cash equivalents | 7675.4 | 9761.9 |
| **Total current assets**  | **16146.6** | **18803.5** |
| **Total assets** | **21988.6** | **22529.7** |
| **Equity and liabilities**  |  |  |
| **Equity**  |  |  |
| Share capital | 259.0 | 248.6 |
| Capital reserve | 2473.3 | 1398.6 |
| Treasury shares | (7.7) | (8.6) |
| Retained earnings | 17961.9 | 19098.0 |
| Other reserves  | (1462.3) | (1325.5) |
| **Total equity**  | **19224.2** | **19411.1** |
| **Non-current liabilities**  |  |  |
| Lease liabilities, loans and borrowings | 215.2 | 214.7 |
| Other financial liabilities  | 94.9 | 46.9 |
| Provisions | 35.5 | 20.9 |
| Contract liabilities | 88.0 | 183.0 |
| Other non-financial liabilities | 104.2 | 87.5 |
| Deferred tax liabilities | 84.3 | 42.4 |
| **Total non-current liabilities**  | **622.1** | **595.4** |
| **Current liabilities**  |  |  |
| Lease liabilities, loans and borrowings | 52.2 | 39.5 |
| Trade payables and other payables | 534.9 | 426.7 |
| Other financial liabilities  | 351.7 | 1443.4 |
| Income tax liabilities | 65.6 | 4.5 |
| Provisions | 145.3 | 144.8 |
| Contract liabilities | 754.9 | 294.9 |
| Other non-financial liabilities | 237.7 | 169.4 |
| **Total current liabilities** | **2142.3** | **2523.2** |
| **Total liabilities**  | **2764.4** | **3118.6** |
| **Total equity and liabilities**  | **21988.6** | **22529.7** |

---

------

![image_0a.jpg](image_0a.jpg)

**Consolidated Statements of Cash Flows**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended** <br>**December 31,**  | **Three months ended** <br>**December 31,**  | **Years ended** <br>**December 31,**  | **Years ended** <br>**December 31,**  |
| | **2025** | **2024** | **2025** | **2024** |
| <br><br>*(in millions €)* | *(unaudited)* | *(unaudited)* |  |  |
| **Operating activities** |  |  |  |  |
| Net profit / (loss) | (305.0) | 259.5 | (1136.1) | (665.3) |
| Income taxes | 77.6 | 41.7 | 85.3 | (12.4) |
| **Profit / (Loss) before tax** | **(227.4)** | **301.2** | **(1050.8)** | **(677.7)** |
| **Adjustments to reconcile loss before tax to net cash flows:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation, amortization and impairment of property, plant, equipment, intangible assets and right-of-use assets | 164.8 | 165.4 | 382.8 | 298.0 |
| &nbsp;&nbsp;&nbsp;Share-based payment expenses | 24.1 | 23.5 | 106.2 | 100.9 |
| &nbsp;&nbsp;&nbsp;Net foreign exchange differences | (43.0) | (32.1) | (6.6) | (109.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) / Loss on disposal of property, plant and equipment | (0.8) | (0.1) | (2.5) | (0.3) |
| &nbsp;&nbsp;&nbsp;Finance income excluding foreign exchange differences | (99.1) | (149.7) | (423.9) | (648.5) |
| &nbsp;&nbsp;&nbsp;Finance expense excluding foreign exchange differences | 4.3 | 12.6 | 21.4 | 27.4 |
| &nbsp;&nbsp;&nbsp;Government grants | (19.5) | (4.7) | (63.0) | (31.5) |
| &nbsp;&nbsp;&nbsp;Other non-cash (income) / loss | 600.4 |  | 585.4 |  |
| &nbsp;&nbsp;&nbsp;Unrealized (gain) / loss on derivative instruments at fair value through profit or loss | 2.5 | 3.9 | (10.4) | 4.6 |
| **Working capital adjustments:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Increase) / Decrease in trade and other receivables, contract assets and other assets | 81.0 | (879.9) | 1083.7 | 387.7 |
| &nbsp;&nbsp;&nbsp;Decrease in inventories | 116.2 | 19.9 | 177.9 | 74.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Decrease) / Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions | (424.6) | 167.7 | (723.8) | 758.4 |
| Interest received and realized gains from cash and cash equivalents | 61.8 | 121.6 | 337.0 | 474.9 |
| Interest paid and realized losses from cash and cash equivalents | (2.8) | (6.6) | (11.0) | (13.5) |
| Income tax received / (paid), net | 40.5 | (198.4) | 3.8 | (389.2) |
| Share-based payments | (6.0) | (10.9) | (25.3) | (154.5) |
| Government grants received | 37.1 | 3.3 | 75.1 | 106.0 |
| **Net cash flows from operating activities** | **309.5** | **(463.3)** | **456.0** | **207.7** |
| **Investing activities** |  |  |  |  |
| Purchase of property, plant and equipment | (63.2) | (66.6) | (175.1) | (286.5) |
| Proceeds from sale of property, plant and equipment | 0.6 | 0.7 | 4.5 | 1.2 |
| Purchase of intangible assets | 1.1 | (24.5) | (573.9) | (165.8) |
| Acquisition of subsidiaries and businesses, net of cash acquired | 264.8 |  | 186.3 |  |
| Investment in other financial assets | (4375.8) | (2068.8) | (11422.5) | (12370.3) |
| Proceeds from maturity of other financial assets | 1446.9 | 2765.9 | 9512.2 | 10740.2 |
| **Net cash flows used in investing activities** | **(2725.6)** | **606.7** | **(2468.5)** | **(2081.2)** |
| **Financing activities** |  |  |  |  |
| Proceeds from loans and borrowings | 6.7 |  | 6.7 |  |
| Repayment of loans and borrowings | (8.6) |  | (18.0) | (2.3) |
| Payments related to lease liabilities | (10.4) | (7.3) | (39.6) | (43.6) |
| Transaction costs related to issuance of share capital | (2.0) |  | (2.0) |  |
| **Net cash flows used in financing activities** | **(14.3)** | **(7.3)** | **(52.9)** | **(45.9)** |
| Net decrease in cash and cash equivalents | (2430.4) | 136.1 | (2065.4) | (1919.4) |
| Change in cash and cash equivalents resulting from exchange rate differences | 1.4 | 13.6 | (27.0) | 14.8 |
| Change in cash and cash equivalents resulting from other valuation effects | 11.5 | (12.4) | 5.9 | 2.8 |
| Cash and cash equivalents at the beginning of the period | 10092.9 | 9624.6 | 9761.9 | 11663.7 |
| **Cash and cash equivalents as of December 31** | **7675.4** | **9761.9** | **7675.4** | **9761.9** |

---

------

![image_0a.jpg](image_0a.jpg)

**Non-IFRS Reconciliation**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Non-IFRS Reconciliation for the year ended December 31, 2025** | **Non-IFRS Reconciliation for the year ended December 31, 2025** | **Non-IFRS Reconciliation for the year ended December 31, 2025** | **Non-IFRS Reconciliation for the year ended December 31, 2025** | **Non-IFRS Reconciliation for the year ended December 31, 2025** | **Non-IFRS Reconciliation for the year ended December 31, 2025** | **Non-IFRS Reconciliation for the year ended December 31, 2025** |
|  |  | **non-IFRS adjustments** | **non-IFRS adjustments** | **non-IFRS adjustments** | **non-IFRS adjustments** |  |
| *(in millions €, except per share data)* | **IFRS Results** | **Expenses and income from legal proceedings** | **Impairment and reversal** | **Employee-related expenses from restructuring** | **Income from bargain purchase and income and expenses from divestiture related items** | **Adjusted Results** |
| Cost of sales | (641.8) |  | 30.5 |  |  | (611.3) |
| Research and development expenses | (2104.9) |  | 85.4 |  |  | (2019.5) |
| Other operating expenses  | (1088.3) | 789.5 | 71.6 | 57.0 |  | (170.2) |
| Other operating income  | 184.6 |  |  |  | (15.0) | 169.6 |
| **Operating loss** | **(1404.9)** | **789.5** | **187.5** | **57.0** | **(15.0)** | **(385.9)** |
| **Loss before tax** | **(1050.8)** | **789.5** | **187.5** | **57.0** | **(15.0)** | **(31.8)** |
| **Net loss**<sup>1</sup> | **(1136.1)** | **789.5** | **187.5** | **57.0** | **(15.0)** | **(117.1)** |
| **Loss per share** |  |  |  |  |  |  |
| Basic loss per share | (4.70) |  |  |  |  | (0.48) |
| Diluted loss per share | (4.70) |  |  |  |  | (0.48) |

---

<sup>1</sup> Tax effects are not considered as part of our non-IFRS adjustments.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Non-IFRS Reconciliation for the three months ended December 31, 2025** | **Non-IFRS Reconciliation for the three months ended December 31, 2025** | **Non-IFRS Reconciliation for the three months ended December 31, 2025** | **Non-IFRS Reconciliation for the three months ended December 31, 2025** | **Non-IFRS Reconciliation for the three months ended December 31, 2025** | **Non-IFRS Reconciliation for the three months ended December 31, 2025** | **Non-IFRS Reconciliation for the three months ended December 31, 2025** |
|  |  | **non-IFRS adjustments** | **non-IFRS adjustments** | **non-IFRS adjustments** | **non-IFRS adjustments** |  |
| *(in millions €, except per share data)* | **IFRS Results** | **Expenses and income from legal proceedings** | **Impairment and reversal** | **Employee-related expenses from restructuring** | **Income from bargain purchase and income and expenses from divestiture related items** | **Adjusted Results** |
| *(in millions €, except per share data)* | *(unaudited)* | **Expenses and income from legal proceedings** | **Impairment and reversal** | **Employee-related expenses from restructuring** | **Income from bargain purchase and income and expenses from divestiture related items** | **Adjusted Results** |
| Cost of sales | (333.3) |  | 30.5 |  |  | (302.8) |
| Other operating expenses  | (208.0) | 111.4 | 71.6 | 12.0 |  | (13.0) |
| **Operating loss** | **(322.8)** | **111.4** | **102.1** | **12.0** | **—** | **(97.3)** |
| **Loss before tax** | **(227.4)** | **111.4** | **102.1** | **12.0** | **—** | **(1.9)** |
| **Net loss**<sup>1</sup> | **(305.0)** | **111.4** | **102.1** | **12.0** | **—** | **(79.5)** |
| **Loss per share** |  |  |  |  |  |  |
| Basic loss per share | (1.25) |  |  |  |  | (0.33) |
| Diluted loss per share | (1.25) |  |  |  |  | (0.33) |

---

<sup>1</sup> Tax effects are not considered as part of our non-IFRS adjustments.

------

![image_0a.jpg](image_0a.jpg)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Non-IFRS Reconciliation for the year ended December 31, 2024** | **Non-IFRS Reconciliation for the year ended December 31, 2024** | **Non-IFRS Reconciliation for the year ended December 31, 2024** | **Non-IFRS Reconciliation for the year ended December 31, 2024** | **Non-IFRS Reconciliation for the year ended December 31, 2024** | **Non-IFRS Reconciliation for the year ended December 31, 2024** | **Non-IFRS Reconciliation for the year ended December 31, 2024** |
|  |  | **non-IFRS adjustments** | **non-IFRS adjustments** | **non-IFRS adjustments** | **non-IFRS adjustments** |  |
| *(in millions €, except per share data)* | **IFRS Results** | **Expenses and income from legal proceedings** | **Impairment and reversal** | **Employee-related expenses from restructuring** | **Income from bargain purchase and income and expenses from divestiture related items** | **Adjusted Results** |
| Cost of sales | (541.3) |  | 48.1 |  |  | (493.2) |
| Research and development expenses | (2254.2) |  | 81.5 |  |  | (2172.7) |
| Other operating expenses  | (811.5) | 657.4 |  |  |  | (154.1) |
| **Operating loss** | **(1314.3)** | **657.4** | **129.6** | **—** | **—** | **(527.3)** |
| **Profit / (Loss) before tax** | **(677.7)** | **657.4** | **129.6** | **—** | **—** | **109.3** |
| **Net profit / (loss)**<sup>1</sup> | **(665.3)** | **657.4** | **129.6** | **—** | **—** | **121.7** |
| **Earnings / (Loss) per share** |  |  |  |  |  |  |
| Basic earnings / (loss) per share | (2.77) |  |  |  |  | 0.51 |
| Diluted earnings / (loss) per share | (2.77) |  |  |  |  | 0.50 |

---

<sup>1</sup> Tax effects are not considered as part of our non-IFRS adjustments.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Non-IFRS Reconciliation for the three months ended December 31, 2024** | **Non-IFRS Reconciliation for the three months ended December 31, 2024** | **Non-IFRS Reconciliation for the three months ended December 31, 2024** | **Non-IFRS Reconciliation for the three months ended December 31, 2024** | **Non-IFRS Reconciliation for the three months ended December 31, 2024** | **Non-IFRS Reconciliation for the three months ended December 31, 2024** | **Non-IFRS Reconciliation for the three months ended December 31, 2024** |
|  |  | **non-IFRS adjustments** | **non-IFRS adjustments** | **non-IFRS adjustments** | **non-IFRS adjustments** |  |
| *(in millions €, except per share data)* | **IFRS Results** | **Expenses and income from legal proceedings** | **Impairment and reversal** | **Employee-related expenses from restructuring** | **Income from bargain purchase and income and expenses from divestiture related items** | **Adjusted Results** |
| *(in millions €, except per share data)* | *(unaudited)* | **Expenses and income from legal proceedings** | **Impairment and reversal** | **Employee-related expenses from restructuring** | **Income from bargain purchase and income and expenses from divestiture related items** | **Adjusted Results** |
| Cost of sales | (243.5) |  | 39.0 |  |  | (204.5) |
| Research and development expenses | (611.8) |  | 81.5 |  |  | (530.3) |
| Other operating expenses | (91.6) | 52.4 |  |  |  | (39.2) |
| **Operating profit** | **148.6** | **52.4** | **120.5** | **—** | **—** | **321.5** |
| **Profit before tax** | **301.2** | **52.4** | **120.5** | **—** | **—** | **474.1** |
| **Net profit**<sup>1</sup> | **259.5** | **52.4** | **120.5** | **—** | **—** | **432.4** |
| **Earnings per share** |  |  |  |  |  |  |
| Basic earnings per share | 1.08 |  |  |  |  | 1.80 |
| Diluted earnings per share | 1.08 |  |  |  |  | 1.79 |

---

<sup>1</sup> Tax effects are not considered as part of our non-IFRS adjustments.

For the three months ended and the year ended December 31, 2023, our adjusted results were identical to our results under IFRS Accounting Standards.

## Exhibit 99.2

![](ex992bntx4qfy2025present001.jpg)

4th Quarter & Full Year 2025 Financial Results & Corporate Update March 10th, 2026 Exhibit 99.2

------

![](ex992bntx4qfy2025present002.jpg)

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech's leadership and the transition of responsibilities at the Management Board; preliminary discussions between BioNTech and the co-founders regarding the potential contribution of certain BioNTech assets to an independent company; BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech's expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; discussions with regulatory agencies; BioNTech's expectations with respect to intellectual property; the impact of BioNTech's collaboration and licensing agreements, including BioNTech's partnership with BMS; BioNTech's expectations with respect to tariff policy; BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech's expectations of net profit / (loss). In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are based on BioNTech's current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward- looking statements. These risks and uncertainties include, but are not limited to: BioNTech's ability to successfully identify and recruit successors for the CEO and CMO positions; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech's other product candidates; the timing of and BioNTech's ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and its product candidates, if approved; BioNTech's ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech's ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Annual Report on Form 20-F for the period ended December 31, 2025, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. Furthermore, certain statements contained in this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and BioNTech's own internal estimates and research. While BioNTech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, any market data included in this presentation involves assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. While BioNTech believes its own internal research is reliable, such research has not been verified by any independent source. In addition, BioNTech is the owner of various trademarks, trade names and service marks that may appear in this presentation. Certain other trademarks, trade names and service marks appearing in this presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this presentation may be referred to without the® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. 2 An abbreviation directory of defined terms can be found at the end of the presentation. To be updated by Legal This Slide Presentation Includes Forward-Looking Statements

------

![](ex992bntx4qfy2025present003.jpg)

1 Progress Highlights Prof. Ugur Sahin, Co-founder & Chief Executive Officer 2 Oncology Execution Prof. Özlem Türeci, Co-founder & Chief Medical Officer 3 Financial Performance Ramón Zapata, Chief Financial Officer 3

------

![](ex992bntx4qfy2025present004.jpg)

Progress Highlights Ugur Sahin, Co-founder & Chief Executive Officer 1 4

------

![](ex992bntx4qfy2025present005.jpg)

Translating Science into Survival Building a Global Immunotherapy Powerhouse 5

------

![](ex992bntx4qfy2025present006.jpg)

2025 and Recent Achievements: Strong Performance and Pipeline Momentum 6 COVID-19 Market Leadership Advanced Key Oncology Programs Executed Key Strategic Deals Strengthened Financial Position Launched variant-adapted COVID-19 vaccine Leading COVID-19 vaccine market share1 Over 25 phase 2 & 3 oncology trials ongoing2 10 novel-combination trials ongoing with pumitamig3 Strategic BMS partnership Acquired Biotheus Acquired CureVac Beat increased 2025 revenue guidance €17.2 billion in cash, cash equivalents and securities4 1. Over 50%, including Italy, Spain, France, Germany, USA, Japan, Australia; 2. Includes Phase 2 or 3 trials for BNT111, BNT113, autogene cevumeran (partnered with Genentech, a member of the Roche Group), gotistobart (partnered with OncoC4), trastuzumab pamirtecan (partnered with DualityBio) and pumitamig (partnered with Bristol Myers Squibb) 3. Partnered with Bristol Myers Squibb (BMS); 4. Cash and cash equivalents plus security investments as of December 31, 2025, reached €17,235.6 million, comprising €7,675.4 million in cash and cash equivalents, €7,158.5 million in security investments disclosed as current financial assets and €2,401.7 million in security investments disclosed as non-current financial assets.

------

![](ex992bntx4qfy2025present007.jpg)

Modalities to Disease Areas Transition to a focused disease area specific approach Late-Stage Acceleration Key late-stage data readouts expected for first wave of oncology assets Oncology Focus in 2026 Combination Therapy Momentum Novel-novel pumitamig1 combination data readouts expected 1 2 3 1. Partnered with Bristol Myers Squibb 7

------

![](ex992bntx4qfy2025present008.jpg)

Building a Multi-Product Company by 2030 Targeting 18+ Late-Stage/Pivotal Trial Readouts Through 2030+ Informing Multiple Launch Opportunities 8 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech's and its collaborators' product candidates, if approved. 2. Expected data readouts may be from interim or final analyses, and in some cases may not translate into commercial launches; Partnered with 3. Bristol Myers Squibb; 4. OncoC4; 5. DualityBio; 6. Genentech, a member of the Roche group; 7. These are Phase 1/2 trials. The anticipated pivotal trials evaluating pumitamig in these tumor types are expected to readout after 2030. Tumor Type Incidence1 Assets Late-Stage/Pivotal Trials Expected Data Readouts2 2026 2027 2028 2029 2030+ Lung 1L NSCLC 400K Pumitamig3 ROSETTA Lung-02 Stage III unresectable NSCLC 65K Pumitamig3 ROSETTA Lung-201 1L NSCLC – PD-L1 ≥ 50% 60K Pumitamig3 ROSETTA Lung-202 2L+ sqNSCLC1 55K Gotistobart4 PRESERVE-003 1L ES-SCLC 80k Pumitamig3 ROSETTA Lung-01 Breast 1L TNBC – all comers 20k Pumitamig3 Phase 3 in China 1L TNBC – CPS < 10 15k Pumitamig3 ROSETTA Breast-01 2L+ HR+ BC1 – HER2-low 55k Trastuzumab-pamirtecan5 DYNASTY Breast-02 Genitourinary 1L RCC 40k Pumitamig3 ROSETTA RCC-2087 1L CRPC 110k BNT324/DB-13115 BNT324-03 Gastrointestinal 1L MSS-CRC 230k Pumitamig3 ROSETTA CRC-203 1L Gastric – HER2-neg, PD-L1+ 40k Pumitamig3 ROSETTA Gastric-204 1L HCC 25k Pumitamig3 ROSETTA HCC-2067 Adj. CRC - ctDNA+ 70k Autogene cevumeran6 BNT122-01 Adj. PDAC 30k Autogene cevumeran6 IMCODE003 Gynecologic 2L+ Endometrial1 – HER2-expressing 10k Trastuzumab-pamirtecan5 Single-arm Phase 2 Trastuzumab-pamirtecan5 Fern-EC-01 Additional Tumors 1L HNSCC 160k Pumitamig3 ROSETTA HNSCC-205 1L HNSCC – PD-L1 CPS ≥ 1, HPV16+ 50k BNT113 AHEAD-MERIT

------

![](ex992bntx4qfy2025present009.jpg)

BioNTech New Company Focus Becoming a multi-product company by 2030 Sharpening focus on growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates Pioneering next-generation mRNA innovations with disruptive potential Next Steps CEO and CMO transition by end of 2026 Executive search underway BioNTech planning to contribute related rights and mRNA technologies in exchange for a minority stake Signing of binding agreements expected by end of H1 2026 Strategic Focus to Maximize Value for Patients and Shareholders 9 The information above is based on a non-binding letter of intent and is subject to the relevant parties entering into a final, definitive agreement.

------

![](ex992bntx4qfy2025present010.jpg)

Oncology Execution Özlem Türeci, Co-founder & Chief Medical Officer 2 10

------

![](ex992bntx4qfy2025present011.jpg)

11 1. Synergistic potential Space for curative approaches Immunomodulators Targeted therapies Synergy1Synergy1 Synergy1 mRNA cancer immunotherapies Focus on the critical IO pathways • Targeting different complementary pathways in cancer immunity cycle may promote a durable anti-tumor effect Eliminate polyclonal residual disease with multi-antigen and individualized approaches • Polyspecific activity by targeting multiple antigens at once • Establish long-lasting immunological memory to prevent relapses Precise and potent modalities for fast onset tumor reduction • ADC as potential "augmenters" of immunomodulators and mRNA cancer immunotherapies • HER2, TROP2, B7H3, HER3, and EGFR/HER3 ADCs as combination partners Multi-Modal Immunotherapy Oncology Strategy

------

![](ex992bntx4qfy2025present012.jpg)

Establish ElevateExpand SCLC 1L Ph3 (Global) 2L Ph3 (China) NSCLC 1L Ph2/3 (Global) 1L NSCLC Stage III unres. Ph3 (Global) 1L NSCLC PD-L1 ≥ 50% Ph3 (Global) TNBC 1L Ph3 trial (Global) 1L Ph3 (China) Pumitamig Strategy to Build a Proprietary IO Franchise 12 1. Partnered with Bristol Myers Squibb. Registrational-Intent 1L Gastric Ph2/3 (Global) 1L CRC Ph2/3 (Global) 1L HNSCC Ph2/3 (Global) Signal-Seeking 1L PDAC Ph2 (China) 1L GBM Ph2 (China) 1L RCC Ph1/2 (Global) 1L HCC Ph1/2 (Global) And others Combining with our ADCs targeting • HER2 • TROP2 • B7H3 Exploring potential synergies with our IO agents • EpCam x 4-1BB • TIGIT x PVRIG • mRNA cancer immunotherapy Broad Pan-Tumor Applicability With Standard-of-Care Chemotherapy 12+ trials exploring pumitamig1 in 10+ new indications Potential New Standards of Care 10+ novel-novel combinations • HER3 • EGFR x HER3 • Novel targets Foundational Registrations Registrational trials with pumitamig1 ongoing in 3 high-impact tumors

------

![](ex992bntx4qfy2025present013.jpg)

Establish ElevateExpand SCLC 1L Ph3 (Global) 2L Ph3 (China) NSCLC 1L Ph2/3 (Global) 1L NSCLC Stage III unres. Ph3 (Global) 1L NSCLC PD-L1 ≥ 50% Ph3 (Global) TNBC 1L Ph3 trial (Global) 1L Ph3 (China) Pumitamig Strategy to Build a Proprietary IO Franchise 13 Registrational-Intent 1L Gastric Ph2/3 (Global) 1L CRC Ph2/3 (Global) 1L HNSCC Ph2/3 (Global) Signal-Seeking 1L PDAC Ph2 (China) 1L GBM Ph2 (China) 1L RCC Ph1/2 (Global) 1L HCC Ph1/2 (Global) And others Combining with our ADCs targeting • HER2 • TROP2 • B7H3 Exploring potential synergies with our IO agents • EpCam x 4-1BB • TIGIT x PVRIG • mRNA cancer immunotherapy Potential New Standards of Care 10+ novel-novel combinations • HER3 • EGFR x HER3 • Novel targets Foundational Registrations Registrational trials with pumitamig1 ongoing in 3 high-impact tumors Broad Pan-Tumor Applicability With Standard-of-Care Chemotherapy 12+ trials exploring pumitamig1 in 10+ new indications 1. Partnered with Bristol Myers Squibb.

------

![](ex992bntx4qfy2025present014.jpg)

Establishing & Expanding Pumitamig1 in Combination with Current SoC 14 1. Partnered with Bristol Myers Squibb. Phase 2 Phase 3 Status Dose Selection Global Initiation Primary Completion SCLC 1L 2028 TNBC 1L 2029 NSCLC 1L 2029 Stg. III unresectable 2026 2030+ 1L PD-L1 ≥50% 2026 2030+ CRC 1L Ongoing 2026 2026 2030 Gastric 1L Ongoing 2026 2026 2030 HNSCC 1L 2026 2026 2026 2030+ HCC 1L Ongoing RCC 1L Ongoing GBM 1L Ongoing in China PDAC 1L Ongoing in China Phase 2 trials to inform pivotal development

------

![](ex992bntx4qfy2025present015.jpg)

Expanding BioNTech's Focus on Lung Cancer to Maximize Pipeline Potential 15 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech's and its collaborators' product candidates, if approved; Partnered with: 2. Bristol Myers Squibb; 3. OncoC4; 4. DualityBio (BNT324/DB-1311, BNT325/DB-1305); 5. MediLink (BNT326/YL202); 6. Being conducted in China. Resectable Stage III Unresectable 1L metastatic 2L+ metastatic Next generation IO Targeted therapy mRNA immunotherapy Registrational trials Ph1/2 PoC trials Gotistobart3 PRESERVE-003 (sq) FixVac + Gotistobart3/ADCs LuCa-MERIT-1 Pumitamig2 + chemo ROSETTA LUNG-01 Pumitamig2 + chemo IIT6 Pumitamig2 + chemo ROSETTA LUNG-02 ADC monos BNT3244, BNT3254, BNT3265 ADC mono BNT3244 Pumitamig2 + ADC (BNT3244) Pumitamig2 + ADCs BNT3244, BNT3254, BNT3265 Pumitamig2 ROSETTA LUNG-201 Pumitamig2 ROSETTA LUNG-202 Pumitamig2 + FixVac LuCa-MERIT-1 Incidence1 80K 35K SCLC Incidence1 220K 65K 400K 230K NSCLC

------

![](ex992bntx4qfy2025present016.jpg)

Establish ElevateExpand SCLC 1L Ph3 (Global) 2L Ph3 (China) NSCLC 1L Ph2/3 (Global) 1L NSCLC St III unres. Ph3 (Global) 1L NSCLC PD-L1 ≥ 50% Ph3 (Global) TNBC 1L Ph3 trial (Global) 1L Ph3 (China) Executing a Parallel Three-Wave Strategy to Build a Proprietary IO Franchise 16 Registrational-Intent 1L Gastric Ph2/3 (Global) 1L CRC Ph2/3 (Global) 1L HNSCC Ph2/3 (Global) Signal-Seeking 1L PDAC Ph2 (China) 1L GBM Ph2 (China) 1L RCC Ph1/2 (Global) 1L HCC Ph1/2 (Global) And others Combining with our ADCs targeting • HER2 • TROP2 • B7H3 Exploring potential synergies with our IO agents • EpCam x 4-1BB • TIGIT x PVRIG • mRNA cancer immunotherapy Potential New Standards of Care 10+ novel-novel combinations • HER3 • EGFR x HER3 • Novel targets 1. Partnered with Bristol Myers Squibb. Foundational Registrations Registrational trials with pumitamig1 ongoing in 3 high-impact tumors Broad Pan-Tumor Applicability With Standard-of-Care Chemotherapy 12+ trials exploring pumitamig1 in 10+ new indications

------

![](ex992bntx4qfy2025present017.jpg)

Single-Agent Activity of ADCs Being Explored Across Indications 17 Partnered with 1. DualityBio; 2. MediLink. Registrational trial Phase 1/2 trial Advancing Single-Agent Towards Commercial Stage T-Pam1 EC Phase 2 fully enrolled with data expected in 2026, confirmatory Phase 3 ongoing T-Pam1 BC Phase 3 fully enrolled with interim data expected in late 2026 BNT324/DB-13111 Phase 3 in 1L mCRPC to start in 2026 BNT326/YL2022 Phase 2 in 2L+ HER2-low/-null BC presented at SABCS 2025 Lung Breast Genitou- rinary Gastrointestinal Gynecologic Additional Tumors N S C L C A G A - N S C L C E G F R m S C L C T N B C H R + / H E R 2 - B C R C C P ro s ta te G C /G E J C R C P D A C H C C E n d o m e tr ia l C e rv ic a l O C G B M H N S C C M e la n o m a T-Pam1 BNT324/ DB-13111 BNT325/ DB-13051 BNT326/ YL2022

------

![](ex992bntx4qfy2025present018.jpg)

Novel Combinations to Expand Pumitamig Opportunity Across Cancer Types 18 Partnered with 1. Bristol Myers Squibb; 2. DualityBio; 3. MediLink. Registrational trial Phase 1/2 trial Building Foundations for Registrational Combinations Generating clinical data from pumitamig1 combined with ADCs 10 novel-novel combination trials ongoing with pumitamig1 Multiple data readouts expected in 2026 P u m it a m ig 1 + Lung Breast Genitou- rinary Gastrointestinal Gyneco -logic Additional Tumors N S C L C A G A - N S C L C E G F R m S C L C T N B C H R + / H E R 2 -B C R C C P ro s ta te G C /G E J C R C P D A C H C C C e rv ic a l O C G B M H N S C C M e la n o m a SoC T-Pam2 BNT324/ DB-13112 BNT325/ DB-13052 BNT326/ YL2023

------

![](ex992bntx4qfy2025present019.jpg)

Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios 19 Partnered with: 1. Genentech, a member of the Roche Group; 2. In collaboration with Regeneron. Autogene cevumeran1 BNT113 BNT1162 Adjuvant 1L Multiple settings CRC Phase 2 PDAC Phase 2 HPV16+ PD-L1 CPS ≥1 HNSCC Phase 2/3 NSCLC Phase 1 & 2 Monotherapy + Atezolizumab + mFOLFIRINOX + Pembrolizumab Mono & combo with IO & ADCs • Recruitment ongoing • Data presented from epi sub-study at ASCO 2024 and from biomarker sub- study at ESMO-GI 2024 • Recruitment ongoing • Data from Phase 1 trial published: Rojas et al., Nature 2023; Sethna et al., Nature 2025 • Recruitment ongoing • Trial updated to Phase 2/3 • Recruitment completed in Phase 2 in 1L NSCLC2 • Data presented at SITC 2023, AACR 2024 and SITC 2024 • Data in frail patients presented at AACR 2025 • Data in patients after CRT presented at WCLC 2025 Phase 2 final analysis expected in 2027 Primary Completion Date in 2031 Phase 3 interim analysis expected in 2026 Individualized Immunotherapy – iNeST1 Off-the-shelf Immunotherapy – FixVac

------

![](ex992bntx4qfy2025present020.jpg)

20 Data from the final analysis of the autogene cevumeran study BNT122-01 were previously expected in 2026. Given events have accrued more slowly than projected, the data from the final analysis are now expected in 2027. Some data readouts may be event-driven and subject to change based on actual event accrual rates. Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. DualityBio; 4. MediLink; 5. Pivotal trial. Program Trial Readout Phase Indication Late-Stage Trial Readouts Trastuzumab-pamirtecan3 Single arm Phase 2 2L+ HER2-expressing endometrial cancer Phase 35 interim analysis Chemo naïve HR+ HER2-low breast cancer Gotistobart2 Phase 35 interim analysis 2L+ sqNSCLC Phase 2 2L+ mCRPC BNT113 Phase 35 interim analysis HPV16+ PD-L1+ HNSCC Pumitamig1 Phase 35 in China interim analysis 1L TNBC Early-Stage Pumitamig & ADC Trial Readouts Pumitamig1 Phase 2 1L NSCLC Phase 2 1L ES-SCLC Phase 2 in China 1L HCC Phase 2 in China 1L MSS-CRC Pumitamig1 + Trastuzumab-pamirtecan3 Phase 1/2 Breast cancer Pumitamig1 + BNT324/DB-13113 Phase 1/2 Advanced solid tumors Phase 2 NSCLC/SCLC Pumitamig1 + BNT325/DB-13053 Phase 2 TNBC Pumitamig1 + BNT326/YL2024 Phase 1/2 NSCLC BNT324/DB-13113 Phase 1/2 2L+ mCRPC Phase 3 Trial Initiations Pumitamig1 Phase 35 1L MSS-CRC 1L HER2- PD-L1+ gastric cancer 1L HNSCC 1L NSCLC – PD-L1 ≥ 50% Stage III unresectable NSCLC BNT324/DB-13113 Phase 3 1L mCRPC BLA Submission Trastuzumab-pamirtecan3 - 2L+ HER2-expressing endometrial cancer Catalyst-Rich Year Ahead with Multiple Expected 2026 Milestones

------

![](ex992bntx4qfy2025present021.jpg)

Financial Performance Ramón Zapata, Chief Financial Officer 3 21

------

![](ex992bntx4qfy2025present022.jpg)

Full Year 2025 Financial Results Compared to Guidance 22 1. Numbers have been rounded. More information can be found in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov. In € millions FY 2025 IFRS Results1 FY 2025 IFRS Guidance Total Revenues 2,870 2,600 – 2,800 R&D Expenses 2,105 2,000 – 2,200 SG&A Expenses 624 550 – 650 Capital Expenditures for Operating Activities 198 200 – 250

------

![](ex992bntx4qfy2025present023.jpg)

Full Year 2025 Financial Results 23 1. All numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Cash and cash equivalents plus security investments as of December 31, 2025, reached €17,235.6 million, comprising €7,675.4 million in cash and cash equivalents, €7,158.5 million in current security investments disclosed as financial assets and €2,401.7 million in non-current security investments disclosed as financial assets. In € millions except per share data1 FY 2025 FY 2024 IFRS Results Adjusted Results2 IFRS Results Adjusted Results2 Revenues 2,870 2,870 2,751 2,751 Cost of sales (642) (611) (541) (493) Research and development expenses (2,105) (2,020) (2,254) (2,173) Sales, marketing, general and administrative expenses (624) (624) (599) (599) Other operating result (904) (1) (671) (14) Operating loss (1,405) (386) (1,314) (527) Net profit / (loss) (1,136) (117) (665) 122 Diluted earnings / (loss) per share (4.70) (0.48) (2.77) 0.50 €17.2 bnBalance Sheet as of December 31, 2025 – Cash and cash equivalents plus security investments3

------

![](ex992bntx4qfy2025present024.jpg)

Fourth Quarter 2025 Financial Results 24 1. All numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Cash and cash equivalents plus security investments as of December 31, 2025, reached €17,235.6 million, comprising €7,675.4 million in cash and cash equivalents, €7,158.5 million in current security investments disclosed as financial assets and €2,401.7 million in non-current security investments disclosed as financial assets. In € millions except per share data1 4Q 2025 4Q 2024 IFRS Results Adjusted Results2 IFRS Results Adjusted Results2 Revenues 907 907 1,190 1,190 Cost of sales (333) (302) (244) (205) Research and development expenses (505) (505) (612) (530) Sales, marketing, general and administrative expenses (218) (218) (132) (132) Other operating result (174) 21 (54) (2) Operating profit / (loss) (323) (97) 149 322 Net profit / (loss) (305) (80) 260 432 Diluted earnings / (loss) per share (1.25) (0.33) 1.08 1.79 €17.2 bnBalance Sheet as of December 31, 2025 – Cash and cash equivalents plus security investments3

------

![](ex992bntx4qfy2025present025.jpg)

Full Year 2026 Financial Guidance1 25 1. Excludes risks that are not yet known and/or quantifiable and related activities. It includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions ("M&A") transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech's Report on Form 20-F for the year ended December 31, 2025 filed on March 10, 2026, which is available at www.sec.gov. In € millions FY 2026 non-IFRS Guidance Total Revenues 2,000 – 2,300 Adjusted R&D Expenses 2,200 – 2,500 Adjusted SG&A Expenses 700 – 800 Revenue Guidance Considerations • Competitive market dynamics in the United States • Begin managing transition of multi-year contracts in Europe, and specifically in Germany where BioNTech recognizes direct sales • Stable revenues from the collaboration with BMS, from a pandemic preparedness contract with the German government, and from the BioNTech Group service businesses • No one-time revenue from Pfizer opt-out from further development of shingles program

------

![](ex992bntx4qfy2025present026.jpg)

2025 2026 – 2029 2030 Advanced Strategy, Matured Pipeline and De-risked Development Drive Oncology Execution at Scale and Speed Diversified Multi- Product Company Progressed key programs into pivotal stage, established partnership with BMS, fortified balance sheet with €17.2 billion in cash1 to fund our pipeline Advance combination therapy studies, accelerate pivotal trial execution, build indication-specific oncology portfolios and execute oncology launches Build a diversified, multi- product global immunotherapy powerhouse addressing high unmet medical need of cancer patients worldwide BioNTech Oncology Vision: Translating Science into Survival 26 1. Preliminary, unaudited figure; consists of cash, cash equivalents and security investments, as of December 31, 2025. i l i i : r l ti i i t r i l

------

![](ex992bntx4qfy2025present027.jpg)

Thank you

------

![](ex992bntx4qfy2025present028.jpg)

Appendix

------

![](ex992bntx4qfy2025present029.jpg)

Reconciliation of Adjusted to IFRS Results – FY 2025 & 2024 Financial Results 29 In € millions except per share data1 FY 2025 FY 2024 IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 2,870 - 2,870 2,751 - 2,751 Cost of sales (642) 31 (611) (541) 48 (493) Research and development expenses (2,105) 85 (2,020) (2,254) 81 (2,173) Sales, marketing, general and administrative expenses (624) - (624) (599) - (599) Other operating result (904) 903 (1) (671) 657 (14) Operating loss (1,405) 1,019 (386) (1,314) 786 (527) Net profit / (loss)3 (1,136) 1,019 (117) (665) 786 122 Basic earnings / (loss) per share (4.70) (0.48) (2.77) 0.51 Diluted earnings / (loss) per share (4.70) (0.48) (2.77) 0.50 1. All numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

------

![](ex992bntx4qfy2025present030.jpg)

Reconciliation of Adjusted to IFRS Results – 4Q 2025 & 2024 Financial Results 30 In € millions except per share data1 4Q 2025 4Q 2024 IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 907 - 907 1,190 - 1,190 Cost of sales (333) 31 (302) (244) 39 (205) Research and development expenses (505) - (505) (612) 82 (530) Sales, marketing, general and administrative expenses (218) - (218) (132) - (132) Other operating result (174) 195 21 (54) 52 (2) Operating profit / (loss) (323) 226 (97) 149 173 322 Net profit / (loss)3 (305) 226 (80) 260 173 432 Basic earnings / (loss) per share (1.25) (0.33) 1.08 1.80 Diluted earnings / (loss) per share (1.25) (0.33) 1.08 1.79 1. All numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

------

![](ex992bntx4qfy2025present031.jpg)

BioNTech's Oncology Pipeline 31 Partnered with: 1. Bristol Myers Squibb; 2. Genentech, a member of the Roche Group; 3. DualityBio; 4. OncoC4; 5. MediLink; 6. Genmab; 7. In collaboration with Regeneron; 8.Trial ongoing in China only; 9.Trial is currently being conducted by or on behalf of BioNTech. Bristol Myers Squibb holds co-exclusive rights to pumitamig. Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 BNT116 Adv. NSCLC BNT324/DB-13113 Multiple solid tumors Pumitamig1 + BNT314/GEN10596 Met. CRC9 Autogene cevumeran2 Adj. CRC Pumitamig1 2L ES-SCLC8 Pumitamig1 or BNT325/DB-1305 + BNT324/DB-13113 Multiple solid tumors9 BNT113 1L HPV16+ HNSCC BNT324/ DB-13113 Met. CRPC Trastuzumab pamirtecan3 Met. BC BNT211 Multiple solid tumors BNT325/DB-13053 Multiple solid tumors Pumitamig1 + BNT3212 Multiple solid tumors Autogene cevumeran2 Adj. PDAC Pumitamig1 2L+ EGFRm NSCLC8 Pumitamig1 1L met. CRC Gotistobart4 Met. NSCLC Trastuzumab pamirtecan3 2L EC BNT314/GEN10596 Multiple solid tumors BNT329 Multiple solid tumors Pumitamig1 + BNT3213 1L HCC8,9 BNT1167 1L adv. NSCLC Pumitamig1 2L Glioblastoma8 Pumitamig1 1L met. Gastric Pumitamig1 1L ES-SCLC BNT317 Multiple solid tumors Gotistobart4 Met. CRPC Pumitamig1 + BNT324/DB-13113 Adv./met. NSCLC and SCLC9 BNT326/YL2025 Multiple solid tumors8 Pumitamig1 1L HCC8 Pumitamig1 1L HNSCC Pumitamig1 1L adv. NSCLC BNT326/YL2025 Multiple solid tumors Gotistobart4 Multiple solid tumors Pumitamig1 + BNT325/DB-13053 Multiple solid tumors9 BNT326/YL2025 Adv./met. BC8 Pumitamig1 1L MPM8 Pumitamig1 1L NSCLC Pumitamig1 Unresectable Stage III NSCLC Pumitamig1 Multiple solid tumors Pumitamig1 + BNT326/YL2025 Multiple solid tumors Gotistobart4 PROC Pumitamig1 2L NEN8 Pumitamig1 2L SCLC8 Pumitamig1 1L adv. HCC Pumitamig1 + BNT326/YL2025 Adv. NSCLC Pumitamig1 1L met. CRC8 Pumitamig1 2L adv./met. NSCLC Pumitamig1 1L adv./met. TNBC Pumitamig1 Adv. RCC Pumitamig1 + Trastuzumab pamirtecan3 Adv./met. BC9 Pumitamig1 1L ES-SCLC8 Pumitamig1 1L met. PDAC8 Pumitamig1 1L adv./met.TNBC8 Pumitamig1 1L adv./met. TNBC8 Trastuzumab pamirtecan3 Multiple solid tumors Pumitamig1 1L/2L+ ES-SCLC Pumitamig1 1L/2L adv./met. TNBC mRNA immunotherapyNext generation immunomodulator Targeted therapy Novel-novel combination PLANNED PLANNED PLANNED PLANNED PLANNED PLANNED PLANNED PLANNED

------

![](ex992bntx4qfy2025present032.jpg)

32 Partnered with: 1. University of Pennsylvania; 2. Pfizer; 3. Fosun Pharma; 4. Funded by the Gates Foundation; 5. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI). mRNAAntibody BioNTech's Infectious Diseases Pipeline Phase 1 Phase 1/2 Phase 2 Commercial BNT1631 HSV BNT162 + BNT1612 COVID-19 – Influenza combination BNT1665 Mpox BNT1622,3 COVID-19 BNT351 HIV BNT1644 Tuberculosis BNT165 Malaria BNT1665 Mpox

------

![](ex992bntx4qfy2025present033.jpg)

33 4-1BB CD137 G7 markets Canada, France, Germany, Italy, Japan, GB, USA (sq) NSCLC (squamous) Non-small cell lung cancer n L nth line GB Great Britain OC Ovarian cancer AACR American Association for Cancer Research GBM Glioblastoma PCD Projected Commercialization Date ADC Antibody-drug conjugate GC/GEJ Gastric/Gastro-esophageal junction cancer PD-(L)1 Programmed cell death protein (ligand) 1 adj. Adjuvant HCC Hepatocellular carcinoma PDAC Pancreatic ductal adenocarcinoma adv. Advanced HER2 (or 3) Human epidermal growth factor receptor 2 (or 3) PoC Proof of concept AGA Actionable oncogenic alteration HIV Human immunodeficiency virus PROC Platinum-resistant ovarian cancer ASCO American Society of Clinical Oncology HNC Head and neck cancer PVRIG Poliovirus receptor-related immunoglobulin B7-H3 B7 Homolog 3 HNSCC Head and neck squamous cell carcinoma R&D Research and development BC Breast cancer HPV Human papilloma virus (ncc/cc)RCC ((non-)clear cell) Renal cell carcinoma BLA Biologics License Applications HR Hormone receptor SABCS San Antonio Breast Cancer Symposium BMS Bristol Myers Squibb HSV Herpes simplex virus (ES)SCLC (Extensive stage) small cell lung cancer CPS Combined positive score IFRS International financial reporting standards SEC U.S. Securities and Exchange Commission CRC Colorectal cancer IIT Investigator initiated trial SG&A Selling, general and administrative expenses (m)CRPC (met.) Castration resistant prostate cancer iNeST Individualized NeoAntigen-Specific Therapy SITC Society of Immunotherapy of Cancer CRT Chemoradiation therapy IO Immuno-oncology SoC Standard of care ctDNA Circulating tumor DNA M&A Merger and acquisitions TIGIT T cell immunoreceptor with Ig and ITIM domains EC Endometrial cancer met. Metastatic TM Trademark EGFR(m) (mutated) Epidermal growth factor receptor MIUC Muscle-invasive urothelial carcinoma TNBC Triple-negative breast cancer EpCAM Epithelial cell adhesion molecule MPM Malignant pleural mesothelioma T-Pam Trastuzumab pamirtecan ESMO European Society for Medical Oncology Mpox Monkeypox TROP2 Trophoblast cell-surface antigen 2 EU4(5) Germany, France, Italy, Spain, (UK) mRNA Messenger ribonucleic acid U.S. United States FixVac Fixed Antigen Vaccine MSS Microsatellite stability UK United Kingdom FY Fiscal year NEN Neuroendocrine neoplasm WCLC World Conference of Lung Cancer Abbreviation Directory

------